Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on June 13, 2016, reporting events occurring on June 7, 2016. The filing pertains to Cocrystal Pharma, Inc., a Delaware corporation headquartered in Tucker, GA. The report addresses a Regulation FD disclosure made by the Chief Medical Officer during the Jefferies 2016 Healthcare Conference.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes
There are no material changes to financial results or operations reported in this filing. The primary disclosure relates to strategic intent regarding the company's stock listing status.
Guidance, Outlook, and Risks
- Strategic Intent: Management disclosed an intention to pursue uplisting to the Nasdaq Stock Market in the coming year.
- Capital Raising: The company indicated it would likely engage in capital-raising efforts in conjunction with a potential Nasdaq uplisting.
- Current Status: The company is not presently engaged in a securities offering and has no specific plans to raise capital at this time.
- Risks and Uncertainties: Management provided no assurances regarding the timing of a Nasdaq application, whether an application will be made, or whether the company's securities will be accepted for listing if applied.
Key Facts for Investor Verification
- Verify the company's current stock listing status and the specific requirements for Nasdaq uplisting.
- Monitor future filings for any formal application to Nasdaq or announcements of capital-raising activities.
- Review the company's cash position in subsequent quarterly reports to assess the necessity and timing of potential capital raises.
- Confirm if the "coming year" timeline for uplisting remains valid in future management commentary.